IP Library › Granted Patent US 12,679,883
Granted Patent B2
US 12,679,883 · App. 17/627,337 · Granted Jul 14, 2026

Innovative production technique for antibody-enzyme

Inventors: Taizo Uda (Oita, JP); Emi Hifumi (Oita, JP)
Assignee: JAPAN SCIENCE AND TECHNOLOGY AGENCY
C07K16/06C07K1/16C07K16/065C07K2317/21
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,679,883
App. No.
17/627,337
Filed
Jan 14, 2022
Granted
Jul 14, 2026
Kind
B2
Art Unit
1678
USPC
530/387.1
Abstract

A method for producing a κ light chain antibody having enzyme activity or improved enzyme activity includes modifying a polynucleotide that encodes a κ light chain antibody having a polypeptide having an amino acid sequence where the 95th amino acid residue from the N-terminal of a variable region by the Kabat classification is a proline residue, to delete or substitute the proline residue and to obtain a polynucleotide that encodes a κ light chain antibody having a polypeptide having an amino acid sequence where the 95th amino acid residue from the N-terminal of a variable region by the Kabat classification is deleted or substituted with an amino acid residue other than a proline residue, and expressing a κ light chain antibody having enzyme activity in an intracellular or extracellular expression system by using an expression vector including the polynucleotide that encodes a κ light chain antibody obtained after modification.

Claims (40)

1 . A method for producing a κ light chain antibody having enzyme activity or improved enzyme activity, the method comprising:

a modification step comprising modifying a polynucleotide that encodes a κ light chain antibody having, as a variable region, a polypeptide having an amino acid sequence in which the 95th amino acid residue from the N-terminal of a variable region by the Kabat classification is a proline residue, by deleting or substituting the proline residue and obtaining a polynucleotide that encodes a κ light chain antibody having, as a variable region, a polypeptide having an amino acid sequence in which the 95th amino acid residue from the N-terminal of a variable region by the Kabat classification is deleted or substituted with an amino acid residue other than a proline residue; and

an expression step comprising expressing a κ light chain antibody having enzyme activity in an intracellular or extracellular expression system by using an expression vector including the polynucleotide that encodes a κ light chain antibody obtained after the modification step.

2 . The production method according to claim 1 ,

wherein the κ light chain antibody is a human κ light chain antibody or a mouse κ light chain antibody.

3 . The production method according to claim 1 ,

wherein a variable region of the κ light chain antibody having enzyme activity or improved enzyme activity is a polypeptide selected from the group consisting of the following (1a) to (3c),

(1a) a polypeptide having an amino acid sequence obtained by deletion or substitution of the 95th proline residue from the N-terminal of a variable region by the Kabat classification in an amino acid sequence represented by SEQ ID NO: 1;

(1b) a polypeptide having an amino acid sequence which is obtained by substitution, addition, or deletion of one or more amino acids in the amino acid sequence of the polypeptide (1a) and in which the 95th amino acid residue from the N-terminal of a variable region by the Kabat classification is deleted or substituted with an amino acid residue other than a proline residue;

(1c) a polypeptide having an amino acid sequence which shares 90% or more identity with the amino acid sequence of the polypeptide (1a) and in which the 95th amino acid residue from the N-terminal of a variable region by the Kabat classification is deleted or substituted with an amino acid residue other than a proline residue;

(2a) an amino acid sequence obtained by deletion or substitution of the 95th proline residue from the N-terminal of a variable region by the Kabat classification in an amino acid sequence represented by SEQ ID NO: 2;

(2b) a polypeptide having an amino acid sequence which is obtained by substitution, addition, or deletion of one or more amino acids in the amino acid sequence of the polypeptide (2a) and in which the 95th amino acid residue from the N-terminal of a variable region by the Kabat classification is deleted or substituted with an amino acid residue other than a proline residue;

(2c) a polypeptide having an amino acid sequence which shares 90% or more identity with the amino acid sequence of the polypeptide (2a) and in which the 95th amino acid residue from the N-terminal of a variable region by the Kabat classification is deleted or substituted with an amino acid residue other than a proline residue;

(3a) an amino acid sequence obtained by deletion or substitution of the 95th proline residue from the N-terminal of a variable region by the Kabat classification in an amino acid sequence represented by SEQ ID NO: 3;

(3b) a polypeptide having an amino acid sequence which is obtained by substitution, addition, or deletion of one or more amino acids in the amino acid sequence of the polypeptide (3a) and in which the 95th amino acid residue from the N-terminal of a variable region by the Kabat classification is deleted or substituted with an amino acid residue other than a proline residue;

(3c) a polypeptide having an amino acid sequence which shares 90% or more identity with the amino acid sequence of the polypeptide (3a) and in which the 95th amino acid residue from the N-terminal of a variable region by the Kabat classification is deleted or substituted with an amino acid residue other than a proline residue.

4 . The production method according to claim 1 ,

wherein a variable region of the κ light chain antibody having enzyme activity or improved enzyme activity is a polypeptide selected from the group consisting of the following (4a) to (7c),

(4a) a polypeptide having an amino acid sequence represented by SEQ ID NO: 4;

(4b) a polypeptide having an amino acid sequence which is obtained by substitution, addition, or deletion of one or more amino acids in the amino acid sequence represented by SEQ ID NO: 4 and in which the 95th amino acid residue from the N-terminal of a variable region by the Kabat classification is deleted or substituted with an amino acid residue other than a proline residue;

(4c) a polypeptide having an amino acid sequence which shares 90% or more identity with the amino acid sequence represented by SEQ ID NO: 4 and in which the 95th amino acid residue from the N-terminal of a variable region by the Kabat classification is deleted or substituted with an amino acid residue other than a proline residue;

(5a) a polypeptide having an amino acid sequence represented by SEQ ID NO: 5;

(5b) a polypeptide having an amino acid sequence which is obtained by substitution, addition, or deletion of one or more amino acids in the amino acid sequence represented by SEQ ID NO: 5 and in which the 95th amino acid residue from the N-terminal of a variable region by the Kabat classification is deleted or substituted with an amino acid residue other than a proline residue;

(5c) a polypeptide having an amino acid sequence which shares 90% or more identity with the amino acid sequence represented by SEQ ID NO: 5 and in which the 95th amino acid residue from the N-terminal of a variable region by the Kabat classification is deleted or substituted with an amino acid residue other than a proline residue;

(6a) a polypeptide having an amino acid sequence represented by SEQ ID NO: 6;

(6b) a polypeptide having an amino acid sequence which is obtained by substitution, addition, or deletion of one or more amino acids in the amino acid sequence represented by SEQ ID NO: 6 and in which the 95th amino acid residue from the N-terminal of a variable region by the Kabat classification is deleted or substituted with an amino acid residue other than a proline residue;

(6c) a polypeptide having an amino acid sequence which shares 90% or more identity with the amino acid sequence represented by SEQ ID NO: 6 and in which the 95th amino acid residue from the N-terminal of a variable region by the Kabat classification is deleted or substituted with an amino acid residue other than a proline residue;

(7a) a polypeptide having an amino acid sequence represented by SEQ ID NO: 7;

(7b) a polypeptide having an amino acid sequence which is obtained by substitution, addition, or deletion of one or more amino acids in the amino acid sequence represented by SEQ ID NO: 7 and in which the 95th amino acid residue from the N-terminal of a variable region by the Kabat classification is deleted or substituted with an amino acid residue other than a proline residue;

(7c) a polypeptide having an amino acid sequence which shares 90% or more identity with the amino acid sequence represented by SEQ ID NO: 7 and in which the 95th amino acid residue from the N-terminal of a variable region by the Kabat classification is deleted or substituted with an amino acid residue other than a proline residue.

5 . The production method according to claim 1 ,

wherein a variable region of the κ light chain antibody having enzyme activity or improved enzyme activity is a polypeptide selected from the group consisting of the following (8a) to (8c),

(8a) an amino acid sequence obtained by deletion or substitution of the 95th proline residue from the N-terminal of a variable region by the Kabat classification in an amino acid sequence represented by SEQ ID NO: 8;

(8b) a polypeptide having an amino acid sequence which is obtained by substitution, addition, or deletion of one or more amino acids in the amino acid sequence of the polypeptide (8a) and in which the 95th amino acid residue from the N-terminal of a variable region by the Kabat classification is deleted or substituted with an amino acid residue other than a proline residue;

(8c) a polypeptide having an amino acid sequence which shares 90% or more identity with the amino acid sequence of the polypeptide (8a) and in which the 95th amino acid residue from the N-terminal of a variable region by the Kabat classification is deleted or substituted with an amino acid residue other than a proline residue.

6 . The production method according to claim 1 ,

wherein a variable region of the κ light chain antibody having enzyme activity is a polypeptide selected from the group consisting of the following (9a) to (9c),

(9a) a polypeptide having an amino acid sequence represented by SEQ ID NO: 9;

(9b) a polypeptide having an amino acid sequence which is obtained by substitution, addition, or deletion of one or more amino acids in the amino acid sequence represented by SEQ ID NO: 9 and in which the 95th amino acid residue from the N-terminal of a variable region by the Kabat classification is deleted or substituted with an amino acid residue other than a proline residue;

(9c) a polypeptide having an amino acid sequence which shares 90% or more identity with the amino acid sequence represented by SEQ ID NO: 9 and in which the 95th amino acid residue from the N-terminal of a variable region by the Kabat classification is deleted or substituted with an amino acid residue other than a proline residue.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 14, 2022
From: UDA, TAIZO; HIFUMI, EMI
To: JAPAN SCIENCE AND TECHNOLOGY AGENCY
Reel/Frame 058659/0577 →
Priority Claims (1)
JP 2019-136403 · Jul 24, 2019 · national
Continuity (1)
Related Publication 20220259290A1 · Aug 18, 2022
References Cited (43)
US 8361469B2 · Hilden · 2013 [cited by examiner]
US 10358497B2 · Nioi · 2019 [cited by examiner]
US 10633429B2 · Uda · 2020 [cited by examiner]
US 20120322135A1 · Uda et al. · 2012 [cited by applicant]
US 20150064203A1 · Uda et al. · 2015 [cited by applicant]
US 20190256576A1 · Uda et al. · 2019 [cited by applicant]
JP 2003521927A · 2003 [cited by applicant]
JP 2006508167A · 2006 [cited by applicant]
JP 2006197930A · 2006 [cited by applicant]
JP 2006347922A · 2006 [cited by applicant]
JP 2007202443A · 2007 [cited by applicant]
JP 2007202444A · 2007 [cited by applicant]
JP 2007202445A · 2007 [cited by applicant]
JP 2010518815A · 2010 [cited by applicant]
JP 2011510047A · 2011 [cited by applicant]
JP 2013535192A · 2013 [cited by applicant]
JP 2014503188A · 2014 [cited by applicant]
JP 2014506257A · 2014 [cited by applicant]
JP 2015501814A · 2015 [cited by applicant]
JP 2017519768A · 2017 [cited by applicant]
WO 0157726A1 · 2001 [cited by applicant]
WO 2004050683A2 · 2004 [cited by applicant]
WO 2011102517A1 · 2011 [cited by applicant]
WO 2012010562A1 · 2012 [cited by applicant]
WO 2012094587A1 · 2012 [cited by applicant]
WO 2012096994A2 · 2012 [cited by applicant]
WO 2013085972A1 · 2013 [cited by applicant]
WO 2013133253A1 · 2013 [cited by applicant]
WO 2015025786A1 · 2015 [cited by applicant]
WO 2015196011A1 · 2015 [cited by applicant]
WO 2019079496A2 · 2019 [cited by applicant]
Abdel-Salam et al. Expression of mouse anticreatine kinase (MAK33) monoclonal antibody in the yeast Hansenula polymorpha. Appl Microbiol Biotechnol (2001) 56:157-164. (Year: 2001). [cited by examiner]
Japan Patent Office, “International Search Report for PCT Application No. PCT/JP2020/028435”, Japan, Sep. 24, 2020. [cited by applicant]
Emi Hifumi et al., Role of the constant region domain in the structural diversity of human antibody light chains, Faseb Journal, 2017, vol. 31, No. 4, p. 1668-1677. [cited by applicant]
Emi Hifumi et al., A novel method of preparing the monoform structure of catalytic antibody light chain, Faseb Journal, 2016, vol. 30, No. 2, p. 895-908. [cited by applicant]
Emi Hifumi et al., Method of imparting enzyme action to antibodies, Proceedings of the 28th symposium on biopolymers science, 2018, pp. 147-148. [cited by applicant]
Taizo Uda et al., Catalytic human antibody light chains capable of cleaving Tau peptides, The 99th Annual Meeting of the Chemical Society of Japan, 2019, 1 F3-49. [cited by applicant]
Jinquan Luo et al., Coevolution of Antibody Stability and Vk CDR-L3 Canonical Structure, Journal of Molecular Biology, 2010, 402, 708-719. [cited by applicant]
Certificate of The 12th Symposium on Biorelevant Chemistry, Jun. 28, 2019. [cited by applicant]
Uda et al., A method for an antibody to possess the enzymatic function (Issue No. 4),2C-09, The 12th Symposium on Biorelevant Chemistry, 2018. [cited by applicant]
Certificate of The 99th CSJ Annual Meeting, Jun. 28, 2019. [cited by applicant]
Hifumi et al., A method to possess an enzymatic function to an antibody (5th report) 3G3-19, The 99th CSJ Annual Meeting, 2019. [cited by applicant]
Japan Patent Office, Office Action issued for Application No. 2021-534071, Japan, Apr. 13, 2024. [cited by applicant]